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Abstract  
Objective. We estimated and compared the risk of clinically identified acquired drug 
resistance under i) immediate initiation (the currently recommended ART initiation 
strategy), ii) initiation with CD4<500, and iii) initiation with CD4<350 cells/mm
3
. 
Design. Cohort study based on routinely collected data from the HIV-CAUSAL 
Collaboration.  
Methods. For each individual, baseline was the earliest time when all eligibility criteria 
(ART-naïve, AIDS-free, and others) were met after 1999. Acquired drug resistance was 
defined using the Stanford classification as resistance to any antiretroviral drug that was 
clinically identified at least 6 months after ART initiation. We used the parametric g-
formula to adjust for time-varying (CD4 count, HIV-RNA, AIDS, ART regimen and drug 
resistance testing) and baseline (calendar period, mode of acquisition, sex, age, 
geographical origin, ethnicity and cohort) characteristics.  
Results. In 50,981 eligible individuals, 10% had CD4 count>500 at baseline, and 63% 
initiated ART during follow-up. Of 2,672 tests for acquired drug resistance, 794 found 
resistance. The estimated 7-year risk (95% CI) of acquired drug resistance was 3.2% 
(2.8,3.5) for immediate initiation, 3.1% (2.7,3.3) for initiation with CD4<500, and 2.8% 
(2.5,3.0) for initiation with CD4<350 cells/mm
3
. In analyses restricted to individuals with 
baseline in 2005-2015, the corresponding estimates were 1.9% (1.8, 2.5), 1.9% (1.7,2.4) 
and 1.8% (1.7,2.2). 
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 Conclusions. Our findings suggest that the risk of acquired drug resistance is very low, 
especially in recent calendar periods, and that immediate ART initiation only slightly 
increases the risk. It is unlikely that drug resistance will jeopardize the proven benefits of 
immediate ART initiation.   
Keywords: comparative effectiveness; drug resistance; HIV; parametric g-formula; when 
to start 
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 Introduction 
Immediate initiation of antiretroviral therapy (ART) upon diagnosis of HIV infection 
results in lower risk of serious clinical events
1,2
 and virus transmission when compared 
with delayed ART initiation
3,4
. Therefore international clinical guidelines now 
recommend immediate ART initiation for all HIV-positive individuals, regardless of CD4 
count.
5-8
 A potential concern is that the more prolonged exposure associated with 
immediate initiation
9
 can increase the risk of acquiring drug resistance, which decreases 
virus susceptibility to specific antiretroviral drugs or drug classes.  
Estimates of the long-term risk of acquired drug resistance under immediate ART 
initiation are needed to fully understand the public health impact of the current guidelines 
for ART initiation and to estimate the number of individuals in need of second line 
therapy.  These estimates, however, will need to be obtained from observational studies 
because the follow-up of the completed randomized trials was relatively short 
1,2
 and no 
other large randomized trials are planned. While several observational studies found that 
ART initiation at high CD4 counts was associated with a lower risk of drug resistance, 
10-
13
 these studies did not adjust for time-varying confounders and used the date of ART 
initiation, rather than the date of entry into care, as the time origin.  
Here we estimate and compare the 7-year risks of acquired drug resistance under 
immediate ART initiation and the previously recommended CD4 count-based initiation 
strategies. To do so, we use data on HIV-positive individuals receiving HIV care in 5 
European countries. 
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 Methods 
Study population  
The HIV-CAUSAL Collaboration is a consortium of prospective HIV cohorts from 
Europe and the Americas. All cohorts record routinely collected data in clinical practice 
within settings with universal access to care. Data collected include patient characteristics 
(age, sex, geographical origin, and transmission category), use of ART (type of regimes 
and dates of start and discontinuation), CD4 cell counts, and plasma HIV-RNA, AIDS-
defining conditions, and deaths. Each cohort submits data in a standardized format 
(http://www.hicdep.org/) to the coordinating center. Ethics approval was granted by the 
ethics committees of each of the participating cohorts according to country-specific 
regulations. 
The analyses presented here are based on data pooled in September 2015 and were 
conducted on 6 cohorts within the Collaboration that contributed data on genotypic drug 
resistance testing conducted as part of routine clinical care (AMACS from Greece, AIDS 
Therapy Evaluation in the Netherlands (ATHENA), CoRIS from Spain, Swiss HIV 
Cohort Study, UK CHIC/UK HIV Drug Resistance Database, and UK Register of HIV 
Seroconverters from the United Kingdom). The analyses were restricted to individuals 
who met the following eligibility criteria after 1999: age ≥18 years and CD4 cell count 
and HIV-RNA measurements within 3 months of each other while AIDS-free and ART-
naïve. Because in the early antiretroviral era ART combinations were suboptimal and the 
drug resistance testing uncommon, we also restricted to individuals who entered a cohort 
on or after January 1, 2000. Follow-up started at baseline, defined as the earliest date that 
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all eligibility criteria were met, and ended at the earliest of detection of acquired drug 
resistance, death, 12 months after the most recent HIV-RNA or CD4 count laboratory 
measurement, cohort-specific administrative censoring, date of pregnancy when known, 
or initiation of an antiretroviral therapy combination not defined as ART (see below). 
Treatment strategies  
We defined initiation of combined ART as initiation of combination of antiretroviral 
drugs including at least two nucleoside reverse transcriptase inhibitors plus either one or 
more protease inhibitors, one nonnucleoside reverse transcriptase inhibitor, one 
entry/fusion inhibitor, or one integrase inhibitor. We compared the following strategies: i) 
immediate ART initiation within 3 months of baseline, ii) initiation within 3 months of a 
CD4 count <500 cells/mm
3
 or an AIDS diagnosis, and iii) initiation within 3 months of a 
CD4 cell count <350 cells/mm
3
 or an AIDS diagnosis
14
.  
Clinical guidelines recommend drug resistance testing at all episodes of virological 
failure in ART treated people
5-8,15
. However, in clinical practice these tests are not always 
performed. Therefore, to ensure that our estimates reflect the real-world frequency of 
both drug resistance testing and clinically identified acquired drug resistance, none of the 
strategies (i)-(iii) imposed a drug resistance test at virological failure. In sensitivity 
analyses (see below), we considered an alternative strategy that imposed a drug resistance 
test at each episode of virological failure. 
Drug resistance 
The outcome was clinically identified, acquired drug resistance up to 7 years after 
baseline. Acquired drug resistance was defined as predicted intermediate or high level 
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resistance to any of the following antiretroviral drugs in use during the study period: 
atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, saquinavir, 
tipranavir (protease inhibitors - PI); lamivudine, emtricitabine, abacavir, didanosine, 
tenofovir, stavudine, zidovudine (nucleoside reverse transcriptase inhibitors - NRTI); 
nevirapine, efavirenz, etravirine, rilpivirine (non-nucleoside reverse transcriptase 
inhibitors - NNRTI). Resistance to integrase inhibitors was not examined because it was 
collected only in one cohort and even in this cohort it was very rare.
16
 Predicted 
resistance was derived using the Genotypic Resistance Interpretation Algorithm, version 
7.0 (HIVdb Program, Stanford University, http://hivdb.stanford.edu). To minimize the 
inclusion of transmitted drug resistance in the outcome definition, mutations conferring 
resistance to a drug class the person had never taken or genotypic tests on blood samples 
collected within 6 months after ART initiation were not considered as acquired drug 
resistance.  
Statistical methods 
Because standard statistical methods cannot appropriately adjust for time-varying 
confounders affected by prior treatment 
17,18
, we used the parametric g-formula to adjust 
for the time-varying confounders CD4 cell count, HIV-RNA level, AIDS, drug resistance 
testing, and treatment class (NNRTI versus non-NNRTI based regime) as well as for 
time-fixed confounders measured at baseline.  
 
The parametric g-formula, a generalization of standardization for time-varying treatments 
and confounders, 
18-20
 estimates the risk of drug resistance that would have been observed 
if all patients in the study had adhered to a particular treatment initiation strategy and 
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none had been lost to follow-up, under the assumptions of no residual confounding, no 
measurement error, and no model misspecification 
19,21
. The estimation procedure for the 
HIV-CAUSAL Collaboration has been described elsewhere 
20
. Briefly, the procedure has 
two steps. First, parametric regression models are used to estimate the joint distribution 
of the outcome, treatment and time-varying covariates conditional on previous treatment 
and covariate history. Second, a Monte Carlo simulation using the above estimates is run 
to simulate the distribution of the post-baseline outcomes and time-varying covariates 
separately under each ART initiation strategy. 
 
For the first step, we fit separate binary logistic regression models for time-varying 
indicators of genotypic testing, detection of an acquired drug resistance after a test, death, 
AIDS-defining condition, ART initiation, measurement of CD4 cell count, measurement 
of HIV RNA, and linear regression models for CD4 cell count and HIV-RNA on the 
natural logarithm scale. All regression models included as covariates the most recent 
value of these time-varying variables using cubic splines, time since last CD4 count and 
HIV-RNA measurements, and the following baseline variables: CD4 cell count (<100, 
100-199,200-349,350-499, ≥500 cells/mm3), HIV-RNA level (<10000,10000-100000, 
>100000 copies/mL), age (<35,35-49,≥50 years), sex, mode of HIV acquisition 
(heterosexual, homo/bisexual, injecting drug users, or other/unknown), calendar year 
(2000-2004, 2005-2010, 2011-2015), testing for transmitted drug resistance (i.e., testing 
done before ART initiation and within 12 months of baseline), geographical origin 
(Western countries, sub-Saharan Africa, other, unknown), ethnicity (white, black, 
unknown) and cohort. All models also included an interaction term for number of months 
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since ART initiation. The g-formula estimates of risk in the presence of competing risks 
(death) can be interpreted as an extension of the sub-distribution cumulative incidence 
function to the setting of time-varying treatments and confounders.
19
 We used a 
nonparametric bootstrap procedure based on 500 samples to obtain percentile-based 95% 
confidence intervals (CIs). 
Like all regression-based methods, the parametric g-formula relies on correct model 
specification. To explore the validity of our parametric assumptions, we compared the 
observed means of the outcome and time-varying covariates with those predicted by our 
models. The time-varying means predicted by our models under observed ART initiation 
were similar to the observed means in the original data (Appendix Figure, 
http://links.lww.com/QAD/B186).  All analyses were conducted with the publicly available 
SAS macro GFORMULA (http://www.hsph.harvard.edu/causal/software/). 
We conducted subgroup analyses in individuals with baseline CD4>500 cells/mm
3
 
(because treatment effectiveness may depend on the initial CD4 count), individuals with 
baseline date at or after 1/1/2005 (because some study participants started antiretroviral 
combinations different from those in current use), and individuals originating from Sub-
Saharan Africa (because patterns of acquired drug resistance and testing might differ by 
geographical origin
22
 due to different HIV subtype and patterns of treatment adherence).  
 
Sensitivity analyses 
The uptake of drug resistance testing was relatively low in our cohorts, even though HIV 
guidelines during the study period recommended testing at every episode of virological 
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failure. While this low uptake is consistent with previous reports from high-income 
countries
23
, it may be partly explained by under-ascertainment of drug resistance testing 
in our cohorts. We therefore conducted two analyses to explore the sensitivity of our 
results to under-ascertainment. First, we estimated the 7-year risk of acquired drug 
resistance if a drug resistance test had been conducted at each episode of virological 
failure.  Second, we estimated the 7-year risk of drug resistance under the assumption that 
acquired drug resistance was present at every episode of virological failure. Virological 
failure was defined as the second of two consecutive HIV-RNA≥400 copies/mL 
measured at least 6 months after ART initiation
7
 preceded by a HIV-RNA≤50 copies/mL.  
Our estimates would be confounded if the decision to test for drug resistance depended 
on treatment adherence, a type of information that is usually not captured in HIV cohort 
data. We therefore compared the estimates with and without adjustment for time-varying, 
self-reported adherence (never missed a dose in the previous four weeks versus missed at 
least one dose) in the Swiss HIV Cohort Study, the only cohort collecting this 
information longitudinally
24,25
. 
Finally, in order to examine the impact of heterogeneity by cohort in the patterns of drug 
resistance testing and the collection of genotyping resistance, we reran the analyses 
excluding each of the 6 cohorts one at a time.    
Results 
Table 1 shows the baseline characteristics of the 50,981 eligible individuals: 80% were 
men, 71% started follow-up after 2004; median [IQR] CD4 cell count and age at baseline 
were 405 [256, 580] cells/mm
3
 and 35 [29, 42] years, respectively.  18,002 (25%) 
individuals had a CD4 count> 500 cells/mm
3
 at baseline. A total of 22,161 individuals 
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(43%) were tested for transmitted drug resistance while ART-naïve and within 12 months 
of baseline; transmitted drug resistance was detected in 6.1% of these tests.  
During a follow-up of 204,914 person-years, 31,969 (63%) individuals initiated ART at a 
median CD4 count of 270 [177, 369] and 5 [1, 20] months after baseline. Of these, 3207 
(10%) initiated ART with CD4 count>500 cells/mm
3
. The most common initial ART 
combinations were NNRTI plus 2 NRTI (64%) and boosted PI plus 2 NRTI (29%). Initial 
combinations containing INI plus 2 NRTI, unboosted PI plus 2 NRTI and 3 NRTI were 
uncommon (3%, 3% and 1%, respectively). The presence of acquired drug resistance was 
tested for in 2,672 samples with median [IQR] HIV-RNA of 2,475 [236, 33,434] 
copies/mL. Factors associated with higher rates of testing were female sex, heterosexual 
HIV transmission group, injecting-drug use and younger age at baseline (Table 2). The 
rate of drug resistance testing declined steadily over time. Similar associations and trends 
by baseline characteristics and calendar period were found for the rates of detection of 
drug resistance and of virological failure (Table 2). Cohorts differed in the rates of drug 
resistance testing and of virological failure (Appendix Table 1, 
http://links.lww.com/QAD/B186).  
There were 1874 episodes of virological failure, of which 617 (33%) were followed by a 
drug resistance test within 12 months. The proportion of episodes of virological failure 
followed by a test increased from 20% in 2000-2004 to 37% and 36% in 2005-2009 and 
2010-2015, respectively. Resistance to any drug was detected in 794 (30%) samples. 
Resistance to NNRTI, NRTI and boosted PI was detected in 512 (19%), 576 (22%), and 
67 (3%) samples, respectively.  
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The observed risk of acquired drug resistance was 2.7% at 7 years after baseline. The 
estimated 7-year risk (95% CI) of acquired drug resistance was 3.2% (2.8,3.5) for 
immediate ART initiation, 3.1% (2.7,3.3) for initiation at CD4<500 cells/mm
3
, and 2.8% 
(2.5,3.1) for initiation at CD4<350 cells/mm
3
. Compared with immediate initiation, the 
risk difference (95% CI) was -0.13% (-0.22,-0.06) under initiation at CD4<500 
cells/mm
3
, and -0.37% (-0.52,-0.22) under initiation at CD4<350 cells/mm
3
 (Figure and 
Table 3).  
When restricting the analyses to individuals with baseline in 2005-2015, the estimated 7-
year risk (95% CI) of acquired resistance was 1.9% (1.8, 2.5) for immediate ART 
initiation, 1.9% (1.7,2.4) for initiation at CD4<500 cells/mm
3
, and 1.8% (1.7,2.2) for 
initiation at CD4<350 cells/mm
3
. When the analyses were restricted to individuals with 
baseline CD4>500 cells/mm
3
 the 7-year risk estimates were 1.6% (1.2,2.3), 1.9% 
(1.4,2.4) and 1.6% (1.2,2.1) for immediate initiation and initiation with CD4<500 and 
CD4<350 cells/mm
3
, respectively. Under immediate ART initiation the estimated 7-year 
risk of acquired drug resistance was 4.4% (3.8,5.0) when we imposed a drug resistance 
test at each episode of virological failure, and 10.9% (10.1,11.4) when we assumed that 
every instance of virological failure was due to acquired drug resistance (Table 4). 
Results did not materially change in the subgroup analyses sequentially excluding each of 
the cohorts (Appendix Table 2, http://links.lww.com/QAD/B186). In the Swiss HIV Cohort 
Study data, the estimates of risk under all strategies adjusting for self-reported adherence 
were similar to the estimates not adjusting for adherence (risk difference <0.4%). 
Discussion 
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In HIV-positive individuals receiving routine clinical care in Europe, we estimated that 
the risk of acquired drug resistance was similar under immediate and delayed ART 
initiation. Compared with ART initiation with CD4<500 cells/mm
3
 or AIDS and 
CD4<350 cells/mm
3
 or AIDS, immediate ART initiation increased the 7-year risk of 
acquired drug resistance by only 0.13% and 0.37%, respectively. The estimated 7-year 
risk of clinically identified acquired drug resistance was approximately 3% under all 
ART initiation strategies. These risks and risk differences were even lower in individuals 
with initial CD4 count>500 cells/mm
3 
and individuals who entered the study after 2004.  
To our knowledge, this is the first study to estimate the public health impact of immediate 
ART initiation on the risk of acquired drug resistance. Previous studies found that higher 
CD4 count at ART initiation was associated with lower risk of resistance
10-13
. Unlike in 
these studies, we quantified the risk of drug resistance since baseline, a proxy of entry 
into HIV care, rather than since ART initiation. Our estimates of risk take into account 
that i) immediate initiation implies longer exposure to ART and thus increased chance of 
drug resistance and ii) the risk of acquiring drug resistance before ART initiation is zero. 
Our findings indicate that it is unlikely that the clinical benefits of early ART initiation 
demonstrated by randomized clinical trials
1,2
 and observational studies 
26-30
 will be 
lessened by development of acquired drug resistance. In high-income countries, the need 
for second line treatments due to the development of acquired drug resistance will 
increase only slightly under the new ART initiation guidelines
5-8
. In particular, our 
findings indicate that in a hypothetical cohort of 1000 patients, immediate initiation 
would imply only 4 additional cases in need of second line treatment over a 7 year period 
compared to initiation with CD4<350 cells/mm
3
 or AIDS. Moreover, because of the 
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increasing use of antiretroviral treatments associated with low drug resistance such as 
integrase inhibitors and new generation PI, which were underrepresented in our data, we 
expect this increase to be even lower in the longer term. Further, the low risk of acquired 
drug resistance after 2004 indicates that acquired drug resistance is becoming a rare 
phenomenon in Europe, though higher among individuals born in Sub-Saharan Africa. 
This is compatible with previous findings from the Swiss HIV Cohort Study
22,31
 and 
generalizes them to other European countries with similar access to health care.   
As in previous studies aimed at estimating the comparative effectiveness of immediate 
ART initiation
27
, we analyzed the data both including all patients regardless of initial 
CD4 count (to estimate the public health impact) and including only patients with high 
CD4 count at baseline (to estimate the effectiveness in this particular subgroup). The low 
risk of drug resistance in the subgroup of individuals with baseline CD4 cell count >500 
cells/mm
3
 alleviates the concern that individuals who are diagnosed with HIV while 
asymptomatic might be less likely to adhere to treatment.  
International and national HIV guidelines recommend testing for transmitted drug 
resistance in all ART-naïve individuals and testing for acquired drug resistance in ART-
treated people after all episodes of virological failure. Despite these recommendations 
only 43% of the people included in our study were known to be tested for transmitted 
drug resistance and only 33% of virological failure episodes were known to be followed 
by an acquired drug resistance test. Our estimates were, however, robust under different 
scenarios of potential under-ascertainment of acquired drug resistance.  
The main strengths of our study are the large sample size of over 50,000 individuals and 
the setting in HIV clinics in Europe that are considered representative of routine clinical 
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practice
32
. Care should be taken with generalizing our results to resource-limited settings 
because of the differences in the HIV epidemics, and availability of viral load 
monitoring, of drug resistance testing facilities and of second and third line therapy.  
This study has several limitations. First, the validity of our estimates relies on the 
assumption that all factors that influenced the decision to initiate ART as well as the risk 
of developing drug resistance were adjusted for. We expect this assumption to 
approximately hold because we adjusted for the most important factors used to decide 
whether to initiate ART such as CD4 count, HIV-RNA and AIDS. Second, our methods 
require all models to be correctly specified. This condition cannot be guaranteed, but it 
seems plausible because our models resulted in simulated data sets with distributions of 
outcome and time-varying covariates similar to those in the original data. Third, we could 
not estimate the long-term effect of immediate initiation because approximately only 
25% of included patients had follow-up longer than 7 years. Fourth, given that only half 
of the patients were genotyped before ART initiation, some resistance-associated 
mutations may, in fact, have been transmitted. It is, therefore, possible that our estimates 
of risk of acquired drug resistance are somewhat pessimistic. Finally, only a small 
proportion of patients initiated treatment with integrase inhibitors, an ART regimen 
currently recommended as first line therapy, therefore we could not appropriately assess 
drug resistance for this drug class. However, according to recent reports, drug resistance 
to integrase inhibitors is very rare and integrase inhibitors-treated patients exhibit low 
rates of virological failure
16,31
.   
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In conclusion, the risk of acquired drug resistance after immediate ART initiation, the 
currently recommended strategy for ART initiation, is very small and not materially 
larger than if treatment is deferred. Therefore, it is unlikely that the benefits of immediate 
ART initiation will be compromised by development of acquired drug resistance in high-
income countries and that immediate initiation will imply a substantial increase in need 
of second line treatments.  Continual efforts should be made to monitor trends in 
transmitted drug resistance and acquired drug resistance in high- and low-income 
countries.    
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 Figure. Risk of acquired drug resistance up to 7 years after baseline by ART initiation 
strategy. HIV-CAUSAL Collaboration 2000-2015. 
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Table 1. Baseline characteristics of the 50,981 included individuals, HIV-CAUSAL Collaboration 2000-
2015. 
Baseline characteristics Eligible 
Initiators 
of ART 
(%) 
Median [IQR] follow-up 
time, years 
CD4 count, cells/mm3 <100 4021 (8%) 86 3.8 [1.9, 6.8] 
100 – 200 4820 (9%) 86 4 [2.0, 6.8] 
200 – 350 11581 (23%) 76 3.9 [2.0, 6.5] 
350 – 500 12557 (25%) 60 3.7 [1.9, 6.0] 
>500 18002 (35%) 44 3.3 [1.7, 5.6] 
HIV-RNA, copies/mL <10000 14491 (28%) 48 3.5 [1.8, 5.9] 
10000 - 100000 22670 (44%) 64 3.8 [1.9, 6.3] 
>100000 13820 (27%) 77 3.7 [1.8, 6.4] 
Sex Male 40933 (80%) 63 3.7 [1.9, 6.2] 
Female 10048 (20%) 62 3.5 [1.8, 6.3] 
Age, years < 35 25001 (41%) 57 3.3 [1.8, 5.8] 
35 – 50 21015 (10%) 67 3.9 [2.1, 6.5] 
>50  4965 (31%) 75 3.7 [2.0, 6.3] 
Mode of HIV acquisition Heterosexual 15743 (31%) 65 3.7 [1.8, 6.3] 
Homo/bi-sexual 29482 (58%)  63 3.8 [2.0, 6.3] 
Injection drug-use 2279 (4%) 54 2.5 [1.3, 5.4] 
Other/unknown 3477 (7%) 59 3.3 [1.8, 5.5] 
Calendar year 2000-2004 14894 (29%) 61 6.7 [3.3, 9.8] 
2005-2009 19254 (38%) 67 4.5 [2.7, 6.0] 
2010 - 2015 16833 (33%) 59 1.9 [1.2, 2.8] 
Region of origin Western countries 19751 (39%) 68 3.8 [2.0, 6.3] 
 Sub-saharan 
Africa 
2233 (4%) 66 3.7 [1.8, 6.2] 
 Rest of the world 4407 (9%) 61 3.3 [1.8, 5.8] 
 Unknown 24590 (48%) 59 3.6 [1.8, 6.3] 
Ethnicity White 20714 (41%) 63 3.9 [2.0, 6.7] 
 Black  7991 (16%) 59 3.4 [1.8, 5.9] 
 Other/unknown 22276 (44%) 64 3.5 [1.8, 5.9] 
Testing for transmitted 
drug resistance 
No 28820 (56%) 63 3.4 [1.8, 6.5] 
Yes 22161 (43%) 63 3.8 [2.1, 6.0] 
Overall 
 
50981 (100%) 62 3.7 [1.9, 6.5] 
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Table 2. Tests for acquired drug resistance and number of episodes of virological failure* and 
corresponding rates per 1000 person-years 6 months after ART initiation. HIV-CAUSAL Collaboration 
2000-2015. 
  
Tests for acquired 
drug resistance 
Tests detecting 
acquired drug 
resistance 
Virological failure 
episodes* 
Baseline 
characteristics  
N 
Tests/1000 
person-years 
N 
Tests/1000 
person-years 
N 
Episodes/1000 
person-years 
Overall 
 
2672 20.1 794 6 1874 14.1 
CD4 count, 
cells/mm3 
<100 449 28.9 207 13.3 227 14.8 
100 – 200 433 23.5 138 7.5 254 13.8 
200 – 350 750 19.3 216 5.6 546 14.1 
350 – 500 487 15.8 111 3.6 403 13 
>500 553 19.1 122 4.2 404 15.3 
HIV-RNA, 
copies/mL 
<10000 435 16 111 4.1 425 15.6 
10000 - 100000 1117 18.4 338 5.6 803 13.2 
>100000 1120 25 345 7.7 646 14.4 
Sex Male 1959 18.1 574 5.3 1300 12 
Female 713 29 220 9 574 23.4 
Age, years 18 – 35 1318 23.9 382 6.9 953 17.3 
35 – 50 1136 18.3 351 5.7 790 12.8 
>50 218 14 61 3.9 131 8.4 
Mode of HIV 
acquisition 
Heterosexual 1087 25.8 367 8.7 778 18.7 
Homo/bi-sexual 1326 16.9 337 4.3 864 11 
Injection drug-use 127 30.1 36 8.5 120 28.5 
Other/unknown 132 17 54 7 102 13.2 
Calendar year 2000-2004 1403 24 486 8.3 1104 18.9 
2005-2009 1069 19 264 4.7 609 10.8 
2010 – 2015 200 11.1 44 2.4 162 9 
Region of origin Western countries 524 9.2 181 3.2 602 10.6 
Sub-Saharan 
Africa 
159 28.2 65 11.5 128 22.7 
Rest of the world 137 13.6 55 5.4 109 10.8 
Unknown 1852 30.9 493 8.2 1035 17.2 
Ethnicity White 1288 22.1 312 5.4 849 14.6 
Black 727 38.1 245 12.8 461 24.2 
Other/unknown 657 11.9 237 4.3 564 10.2 
Testing for 
transmitted drug 
resistance 
No 1478 19 508 6.6 1200 15.5 
Yes 1194 11.1 286 5.2 674 12.2 
*Virological failure was defined as the second of two consecutive HIV-RNA≥400 copies/mL preceded by 
HIV-RNA≤50 copies/mL. 
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Table 3. Seven-year risk of acquired drug resistance and risk difference by ART initiation strategy and 
inclusion criteria. HIV-CAUSAL Collaboration 2000-2015. 
Inclusion criteria 
ART initiation 
strategy 
Risk at 7 
years, % (95% 
CI) 
Risk difference 
(95% CI) 
All patients (N=50,981) 
Immediate  3.2 (2.8,3.5) 0 (Ref.) 
<500 cells/mm3  3.1 (2.7,3.3) -0.13 (-0.22,-0.06) 
<350 cells/mm3 2.8 (2.5,3.0) -0.37 (-0.52,-0.22) 
Baseline in calendar years 
2005-2015 (N=36,087) 
Immediate  1.9 (1.8,2.5) 0 (Ref.) 
<500 cells/mm3 1.9 (1.7,2.4) -0.08 (-0.21,0.04) 
<350 cells/mm3 1.8 (1.7,2.2) -0.15 (-0.39,0.02) 
Baseline CD4 count>500 
cells/mm3 (N= 18,002) 
Immediate  1.6 (1.2,2.3) 0 (Ref.) 
<500 cells/mm3 1.9 (1.4,2.4) 0.22 (-0.18,0.48) 
<350 cells/mm3 1.6 (1.2,2.1) -0.08 (-0.62,0.36) 
Individuals with Sub-Saharan 
Africa as region of  origin 
(N=2233) 
Immediate  6.5 (4.2,9.3) 0 (Ref.) 
<500 cells/mm3 6.2 (4.2,9.1) -0.27 (-0.85,0.11) 
<350 cells/mm3 5.6 (3.7,8.7) -0.90 (-1.67,0.00) 
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Table 4. Sensitivity analyses to examine the role of potential underascertainment of drug resistance 
testing. Estimated 7-year risk of acquired drug resistance and risk difference by ART initiation strategy. 
HIV-CAUSAL Collaboration 2000-2015. 
 
 
 
Outcome 
ART initiation 
strategy 
Risk at 7 years, 
% (95% CI) 
Risk difference 
(95% CI) 
Acquired drug resistance 
under the observed data 
Immediate  3.2 (2.8,3.5) 0 (Ref.) 
<500 cells/mm3  3.1 (2.7,3.3) -0.13 (-0.22,-0.06) 
<350 cells/mm3 2.8 (2.5,3.0) -0.37 (-0.52,-0.22) 
Acquired drug resistance 
assuming a drug resistance 
test at every virological 
failure* episode  
Immediate  4.4 (3.8,5.0) 0 (Ref.) 
<500 cells/mm3 3.8 (3.3,4.3) -0.60 (-0.71,-0.44) 
<350 cells/mm3 3.1 (2.8,3.6) -1.27 (-1.47,-0.99) 
Virological failure* episode  
Immediate  10.9 (10.1,11.4) 0 (Ref.) 
<500 cells/mm3 9.3 (8.6,9.8) -1.58 (-1.74,-1.39) 
<350 cells/mm3 7.5 (6.9,7.8) -3.42 (-3.69,-3.07) 
*Virological failure was defined as the second of two consecutive HIV-RNA≥400 copies/mL preceded by 
HIV-RNA≤50 cells/mm3. 
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